AMPA workshop on challenges faced by investigators conducting Alzheimer's disease clinical trials

Alzheimers Dement. 2011 Jul;7(4):e109-17. doi: 10.1016/j.jalz.2010.05.2020.

Abstract

The recruitment and retention of patients are among the greatest challenges currently being faced by researchers who conduct Alzheimer's disease (AD) clinical trials. To discuss these challenges and other major issues associated with clinical research in AD, an international workshop was organized by the Association Monégasque pour la recherche sur la Maladie d'Alzheimer at Monte Carlo, Monaco, in February 2010, with the participation of leading research experts in the field of Alzheimer's. Key topics discussed were as follows: (1) the selection, recruitment, and retention of clinical trial subjects; (2) international co-operation among researchers; and (3) patient rights and informed consent for participants in clinical trials. This article highlights some of the challenges faced by investigators when conducting clinical trials in AD, and it also offers some recommendations aimed at overcoming these challenges.

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Cholinesterase Inhibitors / therapeutic use
  • Clinical Trials as Topic / methods*
  • Databases, Factual / statistics & numerical data
  • Excitatory Amino Acid Antagonists / therapeutic use*
  • Humans
  • International Cooperation
  • Memantine / therapeutic use*
  • Monaco
  • Patient Rights
  • Patient Selection
  • alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid / metabolism*

Substances

  • Cholinesterase Inhibitors
  • Excitatory Amino Acid Antagonists
  • alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
  • Memantine